222 related articles for article (PubMed ID: 26850270)
1. Divergent adherence estimates with pharmacokinetic and behavioural measures in the MTN-003 (VOICE) study.
van der Straten A; Brown ER; Marrazzo JM; Chirenje MZ; Liu K; Gomez K; Marzinke MA; Piper JM; Hendrix CW;
J Int AIDS Soc; 2016; 19(1):20642. PubMed ID: 26850270
[TBL] [Abstract][Full Text] [Related]
2. Misreporting of Product Adherence in the MTN-003/VOICE Trial for HIV Prevention in Africa: Participants' Explanations for Dishonesty.
Montgomery ET; Mensch B; Musara P; Hartmann M; Woeber K; Etima J; van der Straten A
AIDS Behav; 2017 Feb; 21(2):481-491. PubMed ID: 27858268
[TBL] [Abstract][Full Text] [Related]
3. High levels of adherence to a rectal microbicide gel and to oral Pre-Exposure Prophylaxis (PrEP) achieved in MTN-017 among men who have sex with men (MSM) and transgender women.
Carballo-Diéguez A; Balán IC; Brown W; Giguere R; Dolezal C; Leu CS; Marzinke MA; Hendrix CW; Piper JM; Richardson BA; Grossman C; Johnson S; Gomez K; Horn S; Kunjara Na Ayudhya RP; Patterson K; Jacobson C; Bekker LG; Chariyalertsak S; Chitwarakorn A; Gonzales P; Holtz TH; Liu A; Mayer KH; Zorrilla C; Lama J; McGowan I; Cranston RD
PLoS One; 2017; 12(7):e0181607. PubMed ID: 28750059
[TBL] [Abstract][Full Text] [Related]
4. Accuracy of Self-Report and Pill-Count Measures of Adherence in the FEM-PrEP Clinical Trial: Implications for Future HIV-Prevention Trials.
Agot K; Taylor D; Corneli AL; Wang M; Ambia J; Kashuba AD; Parker C; Lemons A; Malahleha M; Lombaard J; Van Damme L
AIDS Behav; 2015 May; 19(5):743-51. PubMed ID: 25100053
[TBL] [Abstract][Full Text] [Related]
5. Reporting of Adherence in the VOICE Trial: Did Disclosure of Product Nonuse Increase at the Termination Visit?
Mensch BS; Brown ER; Liu K; Marrazzo J; Chirenje ZM; Gomez K; Piper J; Patterson K; van der Straten A
AIDS Behav; 2016 Nov; 20(11):2654-2661. PubMed ID: 26906023
[TBL] [Abstract][Full Text] [Related]
6. Perceptions and Experiences with the VOICE Adherence Strengthening Program (VASP) in the MTN-003 Trial.
van der Straten A; Mayo A; Brown ER; Amico KR; Cheng H; Laborde N; Marrazzo J; Torjesen K
AIDS Behav; 2015 May; 19(5):770-83. PubMed ID: 25384907
[TBL] [Abstract][Full Text] [Related]
7. Perspectives on the utility and interest in a point-of-care urine tenofovir test for adherence to HIV pre-exposure prophylaxis and antiretroviral therapy: an exploratory qualitative assessment among U.S. clients and providers.
Bardon AR; Simoni JM; Layman LM; Stekler JD; Drain PK
AIDS Res Ther; 2020 Aug; 17(1):50. PubMed ID: 32762713
[TBL] [Abstract][Full Text] [Related]
8. Disclosure of pharmacokinetic drug results to understand nonadherence.
van der Straten A; Montgomery ET; Musara P; Etima J; Naidoo S; Laborde N; Hartmann M; Levy L; Bennie T; Cheng H; Piper J; Grossman CI; Marrazzo J; Mensch B;
AIDS; 2015 Oct; 29(16):2161-71. PubMed ID: 26544581
[TBL] [Abstract][Full Text] [Related]
9. Characterizing HIV-Preventive, Plasma Tenofovir Concentrations-A Pooled Participant-level Data Analysis From Human Immunodeficiency Virus Preexposure Prophylaxis Clinical Trials.
Garcia-Cremades M; Vučićević K; Hendrix CW; Jayachandran P; Jarlsberg L; Grant R; Celum CL; Martin M; Baeten JM; Marrazzo J; Anderson P; Choopanya K; Vanichseni S; Glidden DV; Savic RM
Clin Infect Dis; 2022 Nov; 75(11):1873-1882. PubMed ID: 35474481
[TBL] [Abstract][Full Text] [Related]
10. Tenofovir Plasma Concentration from Preexposure Prophylaxis at the Time of Potential HIV Exposure: a Population Pharmacokinetic Modeling and Simulation Study Involving Serodiscordant Couples in East Africa.
Mallayasamy S; Chaturvedula A; Fossler MJ; Sale M; Goti V; Bumpus NN; Marzinke MA; Hendrix CW; Haberer JE;
Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31182536
[TBL] [Abstract][Full Text] [Related]
11. High PrEP uptake and objective longitudinal adherence among HIV-exposed women with personal or partner plans for pregnancy in rural Uganda: A cohort study.
Matthews LT; Atukunda EC; Owembabazi M; Kalyebera KP; Psaros C; Chitneni P; Hendrix CW; Marzinke MA; Anderson PL; Isehunwa OO; Hurwitz KE; Bennett K; Muyindike W; Bangsberg DR; Haberer JE; Marrazzo JM; Bwana MB
PLoS Med; 2023 Feb; 20(2):e1004088. PubMed ID: 36795763
[TBL] [Abstract][Full Text] [Related]
12. Adherence, safety, and choice of the monthly dapivirine vaginal ring or oral emtricitabine plus tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis among African adolescent girls and young women: a randomised, open-label, crossover trial.
Nair G; Celum C; Szydlo D; Brown ER; Akello CA; Nakalega R; Macdonald P; Milan G; Palanee-Phillips T; Reddy K; Tahuringana E; Muhlanga F; Nakabiito C; Bekker LG; Siziba B; Hillier SL; Baeten JM; Garcia M; Johnson S; McClure T; Levy L; Livant E; Jacobson C; Soto-Torres L; van der Straten A; Hosek S; Rooney JF; Steytler J; Bunge K; Parikh U; Hendrix C; Anderson P; Ngure K;
Lancet HIV; 2023 Dec; 10(12):e779-e789. PubMed ID: 37898146
[TBL] [Abstract][Full Text] [Related]
13. Tenofovir-based preexposure prophylaxis for HIV infection among African women.
Marrazzo JM; Ramjee G; Richardson BA; Gomez K; Mgodi N; Nair G; Palanee T; Nakabiito C; van der Straten A; Noguchi L; Hendrix CW; Dai JY; Ganesh S; Mkhize B; Taljaard M; Parikh UM; Piper J; Mâsse B; Grossman C; Rooney J; Schwartz JL; Watts H; Marzinke MA; Hillier SL; McGowan IM; Chirenje ZM;
N Engl J Med; 2015 Feb; 372(6):509-18. PubMed ID: 25651245
[TBL] [Abstract][Full Text] [Related]
14. Sharing of Investigational Drug Among Participants in the Voice Trial.
Moodley J; Naidoo S; Moodley J; Ramjee G
AIDS Behav; 2016 Nov; 20(11):2709-2714. PubMed ID: 27146827
[TBL] [Abstract][Full Text] [Related]
15. Pre-exposure Prophylaxis Adherence Measured by Plasma Drug Level in MTN-001: Comparison Between Vaginal Gel and Oral Tablets in Two Geographic Regions.
Minnis AM; van der Straten A; Salee P; Hendrix CW
AIDS Behav; 2016 Jul; 20(7):1541-8. PubMed ID: 25969178
[TBL] [Abstract][Full Text] [Related]
16. The effectiveness of tenofovir-based pre-exposure prophylaxis for prevention of HIV acquisition among sub-Saharan African women at high risk: a systematic review.
Murewanhema G; Malisheni M; Takah NF
Pan Afr Med J; 2021; 38():308. PubMed ID: 34178226
[TBL] [Abstract][Full Text] [Related]
17. Drug-drug interactions between feminizing hormone therapy and pre-exposure prophylaxis among transgender women: the iFACT study.
Hiransuthikul A; Janamnuaysook R; Himmad K; Kerr SJ; Thammajaruk N; Pankam T; Phanjaroen K; Mills S; Vannakit R; Phanuphak P; Phanuphak N;
J Int AIDS Soc; 2019 Jul; 22(7):e25338. PubMed ID: 31298497
[TBL] [Abstract][Full Text] [Related]
18. Safety and pharmacokinetics of single, dual, and triple antiretroviral drug formulations delivered by pod-intravaginal rings designed for HIV-1 prevention: A Phase I trial.
Vincent KL; Moss JA; Marzinke MA; Hendrix CW; Anton PA; Pyles RB; Guthrie KM; Dawson L; Olive TJ; Butkyavichene I; Churchman SA; Cortez JM; Fanter R; Gunawardana M; Miller CS; Yang F; Rosen RK; Vargas SE; Baum MM
PLoS Med; 2018 Sep; 15(9):e1002655. PubMed ID: 30265679
[TBL] [Abstract][Full Text] [Related]
19. A Phase 1 Randomized, Open Label, Rectal Safety, Acceptability, Pharmacokinetic, and Pharmacodynamic Study of Three Formulations of Tenofovir 1% Gel (the CHARM-01 Study).
Mcgowan I; Cranston RD; Duffill K; Siegel A; Engstrom JC; Nikiforov A; Jacobson C; Rehman KK; Elliott J; Khanukhova E; Abebe K; Mauck C; Spiegel HM; Dezzutti CS; Rohan LC; Marzinke MA; Hiruy H; Hendrix CW; Richardson-Harman N; Anton PA
PLoS One; 2015; 10(5):e0125363. PubMed ID: 25942472
[TBL] [Abstract][Full Text] [Related]
20. A randomized clinical pharmacokinetic trial of Tenofovir in blood, plasma and urine in adults with perfect, moderate and low PrEP adherence: the TARGET study.
Cressey TR; Siriprakaisil O; Klinbuayaem V; Quame-Amaglo J; Kubiak RW; Sukrakanchana PO; Than-In-At K; Baeten J; Sirirungsi W; Cressey R; Drain PK
BMC Infect Dis; 2017 Jul; 17(1):496. PubMed ID: 28705153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
